Fig. 5.

DLaN alters the PER2:LUC bioluminescence rhythms measured in the hippocampus. Representative examples of bioluminescence rhythms measured from the Cntnap2 KO (A) and WT (B) hippocampus under LD and DLaN conditions. Several parameters were measured from the bioluminescence rhythms and analyzed with 2-way ANOVA. Histograms show means ± SEM with the values from individual animals overlaid. Significant (P < 0.05) differences because of treatment are indicated with an asterisk (*) over the treated values while the number sign (#) indicates a genotypic difference. (C) Overall, the amplitude of the rhythms was not altered by treatment (F_(1,32) = 3.566, P = 0.069) or genotype (F_(1,32) = 0.065, P = 0.800). However, the treatment did dramatically reduce the amplitude of the KO rhythms, an effect that was significant in post-hoc tests. (D) There was no difference in the tau (free-running period) measured by treatment (F_(1,32) = 0.205, P = 0.654) or genotype (F_(1,32) = 0.629, P = 0.450). (E, F) Polar plots show the peak phase of the rhythms measured under each condition. The numbers show the phases (ZT) with ZT 0 showing the time of light-onset. The peak phase varied with treatment (F_(1,32) = 20.108, P < 0.001) but not genotype (F_(1,32) = 0.602, P = 0.444). The vector indicates the peak phase and the amplitude relative to WT controls. Overall, DLaN caused a phase advance in both genotypes and decreased the amplitude in the mutants only.